Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab

被引：14

作者：

Pantano, Francesco ^{[1
]}

Russano, Marco ^{[1
]}

Berruti, Alfredo ^{[2
]}

Mansueto, Giovanni ^{[3
]}

Migliorino, Maria R. ^{[4
]}

Adamo, Vincenzo ^{[5
,6
]}

Aprile, Giuseppe ^{[7
,8
]}

Gelibter, Alain ^{[9
]}

Ficorella, Corrado ^{[10
,11
]}

Falcone, Alfredo ^{[12
]}

Russo, Antonio ^{[13
]}

Aieta, Michele ^{[14
]}

Maio, Michele ^{[15
]}

Martelli, Olga ^{[16
]}

Barni, Sandro ^{[17
]}

Napolitano, Andrea ^{[1
]}

Roca, Elisa ^{[2
]}

Quadrini, Silvia ^{[3
]}

Iacono, Daniela ^{[4
]}

Russo, Alessandro ^{[5
,6
]}

Calvetti, Lorenzo ^{[7
,8
]}

Occhipinti, Mario A. ^{[9
]}

Cortellini, Alessio ^{[10
,11
]}

Vasile, Enrico ^{[12
]}

Passiglia, Francesco ^{[13
]}

Imperatori, Marco ^{[14
]}

Calabro, Luana ^{[15
]}

Di Giacomo, Anna M. ^{[15
]}

Petrelli, Fausto ^{[17
]}

Pasquini, Giulia ^{[12
]}

Franchina, Tindara ^{[5
,6
]}

Venditti, Olga ^{[10
,11
]}

Intagliata, Salvatore ^{[2
]}

Galvano, Antonio ^{[13
]}

Fioroni, Iacopo ^{[1
]}

Vincenzi, Bruno ^{[1
]}

Tonini, Giuseppe ^{[1
]}

Santini, Daniele ^{[1
]}

机构：

[1] Univ Campus Biomed, Dept Med Oncol, Via Alvaro Del Portillo 200, I-00128 Rome, Italy

[2] Univ Brescia, ASST Spedali Civili, Dept Med & Surg Specialties Radiol Sci & Publ Hlt, Med Oncol, Brescia, Italy

[3] ASL Frosinone, Med Oncol Unit, Frosinone, Italy

[4] St Camillo Forlanini Hosp, Pulm Oncol Unit, Rome, Italy

[5] Univ Messina, Med Oncol Unit AO Papardo, Messina, Italy

[6] Univ Messina, Dept Human Pathol, Messina, Italy

[7] Univ & Gen Hosp, Dept Oncol, Udine, Italy

[8] San Bortolo Gen Hosp, Dept Oncol, ULSS8 Berica, Vicenza, Italy

[9] Policlin Umberto 1, Med Oncol Unit, Rome, Italy

[10] St Salvatore Hosp, Med Oncol Unit, Laquila, Italy

[11] Univ Aquila, Dept Biotechnol & Appl Clin Sci, Laquila, Italy

[12] Azienda Osped Univ Pisana, Unit Oncol 2, Pisa, Italy

[13] Univ Palermo, Dept Surg & Oncol Sci, Sect Med Oncol, Palermo, Italy

[14] IRCCS CROB, Referral Canc Ctr Basilicata, Div Med Oncol, Dept Oncohematol, Rionero, Vulture, Italy

[15] Univ Hosp Siena, Ctr Immunooncol Med Oncol & Immunotherapy, Dept Oncol, Siena, Italy

[16] Azienda Osped San Giovanni Addolorata, Med Oncol Unit, Rome, Italy

[17] Azienda Osped Treviglio, Div Oncol, Treviglio, Italy

来源：

EXPERT OPINION ON BIOLOGICAL THERAPY | 2020年 / 20卷 / 03期

关键词：

Immunotherapy; Nivolumab; non-Small-Cell Lung Cancer; malignant pleural effusion; IMMUNE CHECKPOINT INHIBITORS; PLEURAL EFFUSION; EFFICACY; DOCETAXEL; SURVIVAL; TRIALS;

D O I：

10.1080/14712598.2020.1724953

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Background: Immune-checkpoint inhibitors have radically changed the treatment landscape of Non-Small-Cell Lung Cancer (NSCLC). It is still unclear whether specific clinical characteristics might identify those patients benefiting from immunotherapy more than others. The aim of this study was to identify clinical characteristics associated with disease-specific survival (DSS), time-to-treatment failure (TTF), objective responses (OR) and progressive disease (PD) in NSCLC patients treated with Nivolumab. Methods: This was a multicenter retrospective study conducted on 294 patients treated with Nivolumab for advanced NSCLC. Results: Of the more than 50 variables analyzed, five showed a significant correlation with DSS: ECOG PS, size of the biggest brain metastasis, number of metastatic sites, toxicity, and malignant pleural effusion. Three variables significantly correlated with TTF: malignant pleural effusion, number of metastatic sites, number of liver metastases. Malignant pleural effusion was the only variable showing a significant correlation with OR, as well as the only one correlating with all the endpoints of the study. Conclusions: This study identified clinical characteristics associated with survival and response during treatment with Nivolumab in NSCLC patients. The unfavorable association between malignant pleural effusion and objective response is a novel finding with important translational implications.

引用

页码：319 / 326

页数：8

共 24 条

[11] NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].

KAPLAN, EL ;

MEIER, P .

JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481

[12] Prognostic Impact of Malignant Pleural Effusion at Presentation in Patients with Metastatic Non-Small-Cell Lung Cancer [J].

Morgensztern, Daniel ;

Waqar, Saiama ;

Subramanian, Janakiraman ;

Trinkaus, Kathryn ;

Govindan, Ramaswamy .

JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (10) :1485-1489

[13] Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis [J].

Nishijima, Tomohiro F. ;

Muss, Hyman B. ;

Shachar, Shlomit S. ;

Moschos, Stergios J. .

CANCER TREATMENT REVIEWS, 2016, 45 :30-37

[14] Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer [J].

Paz-Ares, L. ;

Luft, A. ;

Vicente, D. ;

Tafreshi, A. ;

Gumus, M. ;

Mazieres, J. ;

Hermes, B. ;

Senler, F. Cay ;

Csoszi, T. ;

Fulop, A. ;

Rodriguez-Cid, J. ;

Wilson, J. ;

Sugawara, S. ;

Kato, T. ;

Lee, K. H. ;

Cheng, Y. ;

Novello, S. ;

Halmos, B. ;

Li, X. ;

Lubiniecki, G. M. ;

Piperdi, B. ;

Kowalski, D. M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (21) :2040-2051

[15] DESIGN AND ANALYSIS OF RANDOMIZED CLINICAL-TRIALS REQUIRING PROLONGED OBSERVATION OF EACH PATIENT .2. ANALYSIS AND EXAMPLES [J].

PETO, R ;

PIKE, MC ;

ARMITAGE, P ;

BRESLOW, NE ;

COX, DR ;

HOWARD, SV ;

MANTEL, N ;

MCPHERSON, K ;

PETO, J ;

SMITH, PG .

BRITISH JOURNAL OF CANCER, 1977, 35 (01) :1-39

[16]

Quatromoni JG, 2012, AM J TRANSL RES, V4, P376

[17] Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer [J].

Reck, Martin ;

Rodriguez-Abreu, Delvys ;

Robinson, Andrew G. ;

Hui, Rina ;

Csoszi, Tibor ;

Fulop, Andrea ;

Gottfried, Maya ;

Peled, Nir ;

Tafreshi, Ali ;

Cuffe, Sinead ;

O'Brien, Mary ;

Rao, Suman ;

Hotta, Katsuyuki ;

Leiby, Melanie A. ;

Lubiniecki, Gregory M. ;

Shentu, Yue ;

Rangwala, Reshma ;

Brahmer, Julie R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19) :1823-1833

[18] Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab [J].

Sato, Koichi ;

Akamatsu, Hiroaki ;

Murakami, Eriko ;

Sasaki, Seigo ;

Kanai, Kuninobu ;

Hayata, Atsushi ;

Tokudome, Nahomi ;

Akamatsu, Keiichiro ;

Koh, Yasuhiro ;

Ueda, Hiroki ;

Nakanishi, Masanori ;

Yamamoto, Nobuyuki .

LUNG CANCER, 2018, 115 :71-74

[19] Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma [J].

Schadendorf, Dirk ;

Hodi, F. Stephen ;

Robert, Caroline ;

Weber, Jeffrey S. ;

Margolin, Kim ;

Hamid, Omid ;

Patt, Debra ;

Chen, Tai-Tsang ;

Berman, David M. ;

Wolchok, Jedd D. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (17) :1889-U48

[20]

Sugiura S, 1997, CLIN CANCER RES, V3, P47

← 1 2 3 →